Regeneron Pharmaceuticals (REGN) Total Current Liabilities (2009 - 2026)
Regeneron Pharmaceuticals' (REGN) quarterly Total Current Liabilities came in at $5.1 billion in Q1 2026, up 43.21% year-on-year from $3.6 billion in Q1 2025, and up 16.92% quarter-over-quarter from $4.4 billion in Q4 2025.
Regeneron Pharmaceuticals (REGN) Total Current Liabilities (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $5.1 billion for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 43.21% year-over-year to $5.1 billion in Q1 2026; TTM through Mar 2026 was $5.1 billion, a 43.21% increase from a year earlier, with the FY2025 full-year figure at $4.4 billion, up 10.75% from the prior year.
- Total Current Liabilities grew to $5.1 billion in Q1 2026 per REGN's latest filing, from $4.4 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $5.1 billion in Q1 2026 and bottomed at $2.9 billion in Q3 2022.
- The 5-year median for Total Current Liabilities is $3.6 billion (2025), against an average of $3.6 billion.
- Across the five-year window, Total Current Liabilities declined 22.49% in 2022 and surged 43.21% in 2026, its largest moves.
- Year by year, Total Current Liabilities stood at $3.1 billion in 2022, then grew by 8.98% to $3.4 billion in 2023, then advanced by 15.22% to $3.9 billion in 2024, then increased by 10.75% to $4.4 billion in 2025, then rose by 16.92% to $5.1 billion in 2026.
- Per Business Quant, the three latest REGN Total Current Liabilities figures stand at $5.1 billion (Q1 2026), $4.4 billion (Q4 2025), and $4.4 billion (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 1.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.11 Bn |
| Dec 31, 2025 | 4.37 Bn |
| Sep 30, 2025 | 4.43 Bn |
| Jun 30, 2025 | 3.67 Bn |
| Mar 31, 2025 | 3.57 Bn |
| Dec 31, 2024 | 3.94 Bn |
| Sep 30, 2024 | 3.66 Bn |
| Jun 30, 2024 | 3.51 Bn |
| Mar 31, 2024 | 3.58 Bn |
| Dec 31, 2023 | 3.42 Bn |
| Sep 30, 2023 | 3.60 Bn |
| Jun 30, 2023 | 3.10 Bn |
| Mar 31, 2023 | 3.10 Bn |
| Dec 31, 2022 | 3.14 Bn |
| Sep 30, 2022 | 2.88 Bn |
| Jun 30, 2022 | 3.03 Bn |
| Mar 31, 2022 | 3.01 Bn |
| Dec 31, 2021 | 3.93 Bn |
| Sep 30, 2021 | 3.71 Bn |
| Jun 30, 2021 | 3.73 Bn |